Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (5158)	8/25/1998 12:19:00 AM
From: Anthony Wong	Respond to of 9523

The Independent - Viagra Corner August 25, 1998 Despatches from the Frontiers of Medicine HOSPITAL accident and emergency departments have been warned to ask heart attack victims whether they have taken Viagra, to avoid the risk of a potentially fatal drug interaction. Pfizer, manufacturers of the anti-impotence drug, has written to A&E physicians to alert them to the risk of giving a nitrate, the commonest short-term treatment for a heart attack, to men who have recently taken Viagra. Evidence from the US, where there have been more than two dozen deaths linked with Viagra, has shown that the combination of the two drugs can lead to sudden, large drops in blood pressure. Although Viagra is not yet licensed in Britain, Pfizer said it had issued the warning because some private clinics were prescribing it, legally, on a "named patient" basis, and some men had obtained it, illegally, via the Internet. Jeremy Laurance independent.co.uk

To: flickerful who wrote (5158)	8/25/1998 6:47:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Viagra Clears Hurdle to EU Approval; Go-Ahead Seen on Sept. 15 Bloomberg News August 25, 1998, 6:25 a.m. ET Viagra Clears Hurdle to EU Approval; Go-Ahead Seen on Sept. 15 Brussels, Aug. 25 (Bloomberg) -- Pfizer Inc.'s Viagra is set to get marketing approval in the 15-nation European Union, as long as the blockbuster impotence drug carries a clearer label about its side effects, the European Commission said. A committee of drug experts from EU governments recommended authorizing the sale of Viagra once Pfizer, the second-largest U.S. drugmaker, more clearly spells out the ''undesirable side effects'' on the label, the commission said. It scheduled the final approval for Sept. 15. The scrutiny of the world's best-selling impotence treatment coincides with an international conference on the ailment in Amsterdam this week, attended by representatives of Pfizer, Pharmacia & Upjohn Inc., Astra AB and other companies involved in the market for such drugs. Viagra got the backing of the European Medicines Evaluation Agency, an expert panel that advises European regulators on drug approvals, on May 29. Viagra became one of the best-selling U.S. drugs within weeks of its April introduction, and black-market sales have been reported around the world. EU residents have been traveling to buy Viagra in non-EU countries such as Andorra and Switzerland, where it is already licensed for sale. Pfizer said it could start selling Viagra in 50 countries by the end of the year if it wins EU approval. Viagra won approval from the U.S. Food and Drug Administration in March. The FDA said last month 39 men taking Viagra had died, but a link to the drug hasn't been established. --Alison Jahncke and James G. Neuger in the Brussels bureau (32 quote.bloomberg.com